The link you have selected will take you to a site outside xeneticbio.com.

Xenetic Biosciences, Inc. does not review or control the content of any non-Xenetic Biosciences, Inc. site. Xenetic Biosciences, Inc. does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Xenetic Biosciences, Inc. sites.

Xenetic Biosciences, Inc.

menu
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Partners
    • Careers
  • Technology
    • DNase I Oncology Platform
    • Publications
  • Pipeline
    • Overview
    • XBIO-015
    • XBIO-020
  • News & Media
    • Press Releases
    • Presentations
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • Proxy Materials
    • SEC Filings
    • Corporate Governance
  • Contact
  • Xenetic Biosciences, Inc. on Twitter
  • Xenetic Biosciences, Inc. on Facebook
  • Xenetic Biosciences, Inc. on LinkedIn
Nasdaq: XBIO
News & Media

News & Media

  • Press Releases
  • Presentations

Press Releases

  • All News
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2017
  • 2016
  • 2015
  • 2014

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 12, 2021

Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent

Sep 9, 2021

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 8, 2021

Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

Aug 13, 2021

Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market

Jul 28, 2021

Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market

Jul 26, 2021

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results

May 12, 2021

Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit

May 10, 2021

Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)

Mar 29, 2021

Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

Mar 17, 2021
  • 1
  • 2
  • Next »

Get Email Alerts

Stay informed about our latest news and updates

Sign up Today
© 2025Xenetic Biosciences, Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap